In this article, we will look at the 8 Most Oversold Strong Buy-Rated Stocks to Invest In.
Oversold stocks are getting a fresh look in 2026, but not simply because they are down. After a strong run for equities, the easier gains from multiple expansion appear harder to repeat, which shifts the focus back toward entry points, valuation discipline, and stock selection. That is especially relevant when a stock has been sold off even as Wall Street analysts still broadly view the underlying story favorably. In that kind of market, the question is less about buying weakness blindly and more about whether the market weakness has created a better setup in names the market may have turned too negative on.
That broader setup comes through clearly in institutional commentary. J.P. Morgan Asset Management says many of its best investment ideas focus on “out-of-favor quality stocks,” which suggests upside may now depend more on finding mispriced laggards than simply chasing leadership. Franklin Templeton takes a similar view, noting that “periodic pullbacks are normal” and can create “the best opportunities” to add at more attractive prices. Fidelity is even more direct, telling investors they can use volatility to buy “quality stocks” at “discounted prices.” Taken together, the message is fairly consistent that weakness on its own is not enough, but pullbacks in quality names can open the door to better entry points.
Against this backdrop, we will look at the 8 Most Oversold Strong Buy-Rated Stocks to Invest In.
Our Methodology
We used the Finviz screener to identify stocks with an RSI reading of less than 30 and carry a “Strong Buy” rating from analysts. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
8. Boston Scientific Corporation (NYSE:BSX)
On March 30, 2026, Leerink analyst Mike Kratky said Boston Scientific Corporation (NYSE:BSX) CHAMPION-AF readout met both primary safety and efficacy endpoints, as expected, with results presented at ACC. Mike Kratky noted some nuances in the data that bears may focus on, but said feedback from physicians and key opinion leaders supported confidence in increased WATCHMAN procedure volumes. Mike Kratky described the outcome as not a “home run,” but said the data could support incremental adoption and around 20% growth over the LRP, while adding that shares may remain sensitive to near-term dynamics. Leerink reiterated an Outperform rating on the stock.
Similarly, Wells Fargo said the CHAMPION-AF results were “good, not great,” noting the data is unlikely to accelerate WATCHMAN growth due to a slightly higher ischemic stroke rate. Wells Fargo said the device was non-inferior to oral anticoagulants on the primary endpoint but performed worse numerically on stroke rates, leading the firm to lower estimates while maintaining an Overweight rating.
On March 29, 2026, Boston Scientific announced the CHAMPION-AF global clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the WATCHMAN FLX device against non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation. The trial enrolled 3,000 patients and showed a 45% relative reduction in non-procedural bleeding risk, and a 34% reduction when including procedural bleeding. The primary efficacy endpoint was also met, with the device achieving statistical non-inferiority compared to oral anticoagulants.
Boston Scientific Corporation (NYSE:BSX) develops, manufactures, and markets medical devices for interventional medical specialties worldwide.
7. T1 Energy Inc. (NYSE:TE)
On March 31, 2026, T1 Energy Inc. (NYSE:TE) maintained its 2026 production and sales guidance of 3.1–4.2 GW. The company said it is sourcing cells during the 2026 bridge year through international suppliers with certified non-FEOC status, ahead of the expected start of G2_Austin production. T1 plans to produce between 3.1–4.2 GW of modules at G1_Dallas using cells from an expanding global vendor network and said it is increasingly confident in procuring supply toward the high end of that range.
The company reported Q4 revenue of $358.6M, below the $368.2M consensus estimate. CEO Dan Barcelo described 2025 as a “defining year,” citing expanded partnerships, production ramp at G1_Dallas, and over $440M in capital raised. Dan Barcelo also pointed to progress on the G2_Austin facility, transactions tied to Section 45X tax credits, and efforts to build a vertically integrated U.S. solar supply chain.
On March 18, 2026, T1 Energy said Norway’s grid operator Statnett assigned 50MW of power to its Mo i Rana facility, while the company remains in the queue for 396MW and is awaiting a decision on an additional 60MW allocation. The company said the 50MW allotment runs through 2033 and will require supporting infrastructure to serve potential data center demand by Q2 2027. Pareto Securities has been engaged to evaluate options to maximize shareholder value for the site.
T1 Energy Inc. (NYSE:TE) manufactures and sells photovoltaic solar modules and provides energy solutions across the United States, Norway, and other markets.
6. Maze Therapeutics, Inc. (NASDAQ:MAZE)
On March 31, 2026, JPMorgan raised the price target on Maze Therapeutics, Inc. (NASDAQ:MAZE) to $58 from $52 and maintained an Overweight rating. JPMorgan cited a higher probability of success for MZE829 following Phase 2 data and said the drug appears “directionally better” in the focal segmental glomerulosclerosis population.
On March 25, 2026, H.C. Wainwright raised its price target on Maze Therapeutics, Inc. (NASDAQ:MAZE) to $110 from $60 and maintained a Buy rating, saying Phase 2 HORIZON data showed “unambiguously positive” efficacy in APOL1-mediated kidney disease. H.C. Wainwright added that MZE829 has a “best-in-class profile” and a “de-risked regulatory path.”
On March 25, 2026, Maze Therapeutics reported Q4 EPS of (65c), compared to the (78c) consensus estimate. Cash, cash equivalents, and marketable securities were $360.0 million as of December 31, 2025, compared to $196.8 million as of December 31, 2024, and the company expects its current cash position to fund operations into 2028. On the same day, the company announced positive topline data from the Phase 2 HORIZON trial, reporting a 35.6% mean reduction in proteinuria at week 12, with 50% of patients achieving more than a 30% reduction, and said it plans to continue enrollment and advance MZE829 into a pivotal program.
Maze Therapeutics, Inc. (NASDAQ:MAZE) develops small molecule precision medicines for kidney and metabolic diseases.
While we acknowledge the potential of MAZE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MAZE and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Most Oversold Strong Buy-Rated Stocks to Invest In.
Disclosure: None. Follow Insider Monkey on Google News.
